FOURIER试验:低脂蛋白(a)水平的安全性
FOURIER试验纳入27 564例稳定动脉粥样硬化性心血管疾病患者,随机接受依洛尤单抗或安慰剂治疗,评估脂蛋白(a)与不良结局的关系。结果显示,低Lp(a)水平与出血性卒中、严重出血、神经认知事件、恶性肿瘤或房颤风险无关,但与基线及随访期间糖尿病风险增加相关。
要点
- 低Lp(a)水平未增加出血性卒中、严重出血、神经认知事件、恶性肿瘤或房颤风险。
- Lp(a)每降低50 nmol/L,基线糖尿病患病风险及随访新发糖尿病风险均增加。
- 依洛尤单抗不增加糖尿病风险,无论基线Lp(a)水平如何。
核心结论
- 在动脉粥样硬化性心血管疾病患者中,低Lp(a)浓度与大多数不良安全结局风险增加无关,但与基线及新发糖尿病风险增加相关。
研究设计与样本
- FOURIER试验随机纳入27 564例稳定动脉粥样硬化性心血管疾病患者,在接受他汀治疗基础上随机接受依洛尤单抗或安慰剂治疗。
- 基线Lp(a)在25 090例参与者中评估,中位37 nmol/L(四分位距13-165)。
主要发现
- Lp(a)浓度与出血性卒中、严重出血、神经认知事件、恶性肿瘤或房颤的发生风险无关联,包括Lp(a)≤13 nmol/L者。
临床怎么用
- 对于动脉粥样硬化性心血管疾病患者,低Lp(a)水平未被发现增加多数不良安全结局风险,但需关注糖尿病风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Lipoprotein(a) (Lp(a)) is considered a causal risk factor for atherogenesis. A higher prevalence of certain adverse events, including diabetes mellitus (DM), has been reported for patients with low Lp(a) concentrations. Therapeutics that lower Lp(a) are now in clinical testing. Thus, the association between lower Lp(a) concentration and safety outcomes is of clinical importance. METHODS: The FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial randomized 27 564 patients with stable atherosclerotic cardiovascular disease (ASCVD) to evolocumab versus placebo on a background of statin therapy. The relationship between Lp(a) and the risk of prevalent and incident adverse outcomes of interest was examined, adjusting for relevant predictors. RESULTS: Lp(a) was assessed in 25 090 participants at baseline (median 37 nmol/L, interquartile range 13-165). There was no association between Lp(a) concentration and incident risk of haemorrhagic stroke, serious bleeding, neurocognitive events, malignancy, or atrial fibrillation, including those with Lp(a) levels ≤13 nmol/L. There was an inverse association between lower baseline Lp(a) levels and prevalent DM at baseline (adjusted odds ratio 1.03, 95% confidence interval [CI] 1.02-1.04, P < .001; for every 50 nmol/L lower Lp(a)), as well as the incident risk of developing DM during follow-up (adjusted hazard ratio [HR] 1.05, 95% CI 1.02-1.08, P = .002; for every 50 nmol/L lower Lp(a)), with consistent results by treatment arm. Evolocumab did not increase the risk of DM irrespective of baseline Lp(a), even in participants in the top decile of baseline Lp(a) (adjusted HR .72, 95% CI .38-1.35) in whom evolocumab reduced Lp(a) by a median of 71 nmol/L. CONCLUSIONS: In patients with ASCVD, low Lp(a) concentration was not associated with an increased risk of most adverse safety outcomes, but lower Lp(a) was associated with an increased risk of prevalent and incident DM.
引用
- Gencer B, Giugliano RP, Ran X, et al. Safety of low lipoprotein(a) levels: the FOURIER trial. Eur Heart J. 2026. PMID: 42234492. doi:10.1093/eurheartj/ehag398
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。